 |
인쇄하기
취소
|
Handok enters licensing agreement for Cetrorelix with AEterma Zentaris
Handok Pharm announced on July 14 that it has entered into a licensing agreement with Canada-based AEterma Zentaris Inc. for Cetrorelix (cetrorelix pamoate), a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist
Under the terms of the agreement, Handok will have an exclusive license to develop and market Cetrorelix for the treatment of benign prostatic hyperplasia (...
Under the terms of the agreement, Handok will have an exclusive license to develop and market Cetrorelix for the treatment of benign prostatic hyperplasia (...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.